Power Law company profile

HitGen

Biotech & Life Sciences · Chengdu, China · Founded 2012 · IPO 2020 Colt

HitGen is a platform company based on its leading DNA-encoded library (DELs) technology for innovative drug discovery research

Valuation

$1.47B

Market cap · May/2026

Revenue

$59M

Latest reported FY

EBITDA

$17M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

2 investors on HitGen's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 2 investors entered at this stage

Leadyond capital

CDH Investments

Global footprint

Where HitGen has talent and traffic

Workforce by country

🇨🇳 China · Chengdu HQ

Book a demo for the full country breakdown

Web traffic by country

3.9K monthly visits
across markets

🇺🇸 United States48.7%

🇯🇵 Japan41%

🇮🇳 India5.1%

🇬🇧 United Kingdom5.1%

Top 4 markets shown

Market sentiment

What the market is saying about HitGen

An AI-synthesized read of the highest-engagement posts about HitGen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HitGen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles